Vascular Endothelial Growth Factor Inhibitor-Induced Hypertension: Basics for Primary Care Providers

Table 1

Current VEGF kinase inhibitors in use in the United States [10–15].

Name; (proprietary name)	Bevacizumab; (Avastin)	Sorafenib; (Nexavar)	Sunitinib; (Sutent)	Nilotinib; (Tasigna)	Pazopanib; (Votrient)	Dasatinib; (Sprycel)
Mechanism of action	Anti-VEGF monoclonal antibody	Tyrosine kinase inhibitor; VEGF inhibitor	Tyrosine kinase inhibitor; VEGF inhibitor	Tyrosine kinase inhibitor	Tyrosine kinase inhibitor; VEGF inhibitor	Tyrosine kinase inhibitor
Hypertension (%)any grade	23–67	9–17	15–30	1–10	40	1–10
Hypertension (%); grade 3 or more	5–18	Grade 3: 3–4; grade 4: <1	4–10	Not reported	Grade 3: 4	Not reported
FDA-labeled indication	GBM; Metastatic breast cancer; Metastatic colorectal cancer; Non-small cell lung cancer	Liver carcinoma; Renal cell carcinoma	GI stromal tumor; Renal cell carcinoma	CML	Advanced renal cell carcinoma	CML

Abbreviations: VEGF, vascular endothelial growth factor; FDA, Food and Drug Administration; GBM, glioblastoma multiforme; CML, chronic myelogenous leukemia; GI, gastrointestinal.